<!DOCTYPE html>
<html>

	<head>
		<title>B*CURED</title>
		<link rel="stylesheet" type="text/css" href="css/style.css">
	</head>

	<body>
		<header>
			<nav>
			<a href="#">Home</a>
			<a href="#">About Us</a>
			<a href="#">Grants</a>
			<a href="#">Get Involved</a>
			<a href="#">Resources</a>
			<a href="#">Contact Us</a>
			</nav>
			<img src="images/asterik.jpg" alt="bcured asterik logo" title="bcured asterik logo"
		</header>

		<main>
			<h1>B*CURED</h1>
			<h2 id="slogan">connecting passion with innovation to cure brain cancer</h2>
			<img src="images/batter.jpg"
			alt="description" title="searchable title">
			<img src=""
			<img src=""
			<h2><p>It takes years to become a researcher, it takes a minute to become a supporter</h2>
			<a href="">Donate Now</a></p>

	
	<h3>Grants</h3>
	<p>B*CURED's primary goal is to fund innovative brain cancer research to end brain cancer.</p>
	<p>Our funding for the following grants bring us closer to finding a cure.</p>

	<p>We invite clinical doctors and research scientists whose principal focus is brain cancer to apply for our grants. Clinical and translational projects with significant clinical promise will be considered.</p>

	<p>Since it's establishment in 2008, B*CURED has funded 21 programs at prominent US hospitals and universities.</p>

	<p>For further information, please contact us at research@bcured.org.</p>
	<a href="#">Donate Now
B*CURED'S GRANTS TO DATE

	<h4>2016:</h4>
	<ul>
	<li>Manish Aghi, MD, University of California, San Francisco "Defining Gene Expression Profiles of Tumor-Associated Neutrophils in Glioblastoma to Develop Novel Therapeutic Approaches (Immunotherapy)"</li>

	<li>Justin Lathia, MD, Cleveland Clinic "Reversing Immune Cell Suppression in Glioblastoma by Targeting Myeloid-derived Suppressor Cells (Immunotherapy)"</li>

	<li>Elias Sayour, MD, University of Florida, McKnight Brain Center "Host Immunomodulatory RNA-nanoparticles targeting malignant canine glioma (Immunotherapy)"</li>

	<li>David J. Robbins, MD, University of Miami "Identification of Novel Inhibitors to Treat Childhood Brain Tumors" (Rare Deadly Childhood Cancer)</li>

	<li>Markus Siegelin, MD,  Columbia University "Induction of Synthetic Lethality in IDH1 Mutated Gliomas"</li>

	<li>B*CURED - NREF Partnership Grantee:

	James Purzner, MD, Stanford University "Exploring the Epigenetic Regulation of Neuronal Differentiation to Differentiate Medulloblastoma Cells (Pediatric Cancer)"</li>
	</ul>
	<h4>2008 to 2015:</h4>
	<ul>
	<li>Thomas deRaedt,  Brigham and Women's Hospital (Harvard) “Developing a fast, powerful in vivo screening tool for cooperating drivers in GBM”</li>

	<li>Sean Lawler, Brigham and Women's Hospital (Harvard) “Development of novel brain penetrating, glioma-specific nanomedicines as brain cancer therapeutics”</li>

	<li>Carl LeKaye,  Memorial Sloan-Kettering Cancer Center “In vivo MR characterization of response to IDH1 R132H inhibition in preclinical glioma models”</li>

	<li>Mariano Viapiano,  Brigham and Women's Hospital (Harvard) “Engineering a brain-penetrating reagent against the microenvironment of malignant brain tumors”</li>

	<li>Dimitris Placantonakis, MD, PhD, NYU School of Medicine, “Role of GPR133 in Glioblastoma Stem Cell Biology”</li>

	<li>Sunitha Thakur, PhD, Memorial Sloan-Kettering Cancer Center, “MRI Spectroscopy Quantification of the 2-Hydroxyglutarate (2HG) Oncometabolite in Mutant lsocitrate Dehydrogenase (IOH) Brain Glioma”</li>

	<li>Brain Nahed, MD, Massachusetts General Hospital, “Identification and Analysis of Circulation Brain Tumor Cells” <a ref="#">(See published work here).</li>

	<li>Jennifer Yu, MD, PhD, Cleveland Clinic, “Hyperthermia Overcomes Radio Resistance of Glioblastoma Initiating Cells</li>

	<li>Thomas Kaley, MD, PhD, Memorial Sloan-Kettering Cancer Center, “Tumor Treating Fields with Novo TTF for recurrent Atypical and Anaplastic Meningioma”</li>

	<li>Jiangbing Zhou, Yale University Medical School, “Targeted delivery of combination therapy for GBM using multi-functional ultrasmall nanoparticles loaded with siRNAs”</li>

	<li>Andrew Lassman, MD, New York Presbyterian/Columbia University Medical Center, “Pulsatile Kinase Inhibitor Therapy for Malignant Glioma: Proof of Concept Clinical Trial”</li>

	<li>Antonio Omuro, MD, Memorial Sloan-Kettering Cancer Center, “Phase 1 Trial of 929097 in Combination with Standard Radiotherapy and Temozolomide for Newly Diagnosed Malignant Glioma: a Pharmacokinetic and Pharmacodynamic study”</li>

	<li>William Curry, MD, Massachusetts General Hospital, “Host Antitumor Immunity in Glioma Patients Vaccinated with Autologous Irradiated Tumor Cells”</li>

	<li>Ingo Mellinghoff, MD, Memorial Sloan-Kettering Cancer Center, “Development of Biomarkers to Evaluate Kinase Inhibitor Response in Glioma”</li>
	</ul>

	<p>FOR RESEARCHERS: Our grant application deadline is April 1st. The 2017 grant program is now CLOSED.</p> 


	<h4>Events</h4>
	<h4>Our Stories</h4>
	
</main>
</body>
</html>
